Stassen F L, Schmidt D B, Papadopoulos M, Sarau H M
Department of Molecular Pharmacology, Smith Kline & French Laboratories, Philadelphia, Pennsylvania 19101.
J Biol Chem. 1989 Mar 25;264(9):4916-23.
Arginine vasopressin (AVP)-induced formation of inositol phosphates and increased calcium efflux in smooth muscle cells (A-10) were inhibited by short term treatment with phorbol 12,13-dibutyrate (PDBu), an activator of protein kinase C (Ca2+/phospholipid-dependent protein kinase) (Aiyar, N., Nambi, P., Whitman, M., Stassen, F. L., and Crooke, S. T. (1987) Mol. Pharmacol. 31, 180-184). Here we report that prolonged treatment of A-10 cells (48 h) with PDBu markedly enhanced AVP-induced calcium mobilization but inhibited ATP- and thrombin-induced calcium mobilization. PDBu (400 nM) doubled [Ca2+]i induced with 3 nM AVP, while the basal calcium concentrations before and after AVP were not different from those of untreated cells. The EC50 for a 24-h exposure was 2.3 nM PDBu. Phorbol 12-myristate 13-acetate was also effective, while 4-alpha-phorbol 12,13-didecanoate (48 h at 400 nM) was without effect. 4-alpha-phorbol 12,13-didecanoate also did not affect inositol phosphate formation. PDBu markedly enhanced inositol phosphate formation induced by AVP but not by NaF. PDBu did not affect basal inositol phosphate and polyphosphoinositide levels, and cytosolic and membrane-associated phospholipase C activity. PDBu treatment (48 h, 400 nM) decreased membrane-associated and cytosolic protein kinase C activity by 80 and 90%, respectively. However, the dose response and time course of changes in protein kinase C activity did not correlate with the same curves for PDBu enhancement of AVP-induced calcium mobilization. We conclude that prolonged PDBu treatment selectively enhanced AVP-induced calcium mobilization and polyphosphoinositide hydrolysis. These effects were not caused by an increase in vasopressin receptor number and apparent affinity, an increase in phospholipase C activity, G-protein-phospholipase C coupling, formation of polyphosphoinositide, or inhibition of inositol phosphate metabolizing enzymes. Enhancement of the AVP responses did not correlate with desensitization or activation of protein kinase C. We suggest that prolonged PDBu treatment might sensitize a putative V1 receptor-G-protein-phospholipase C complex.
精氨酸加压素(AVP)诱导的平滑肌细胞(A-10)中肌醇磷酸的形成及钙外流增加,可被佛波醇12,13 - 二丁酸酯(PDBu)短期处理所抑制,PDBu是蛋白激酶C(Ca²⁺/磷脂依赖性蛋白激酶)的激活剂(艾亚尔,N.,南比,P.,惠特曼,M.,斯塔森,F. L.,和克鲁克,S. T.(1987年)《分子药理学》31卷,180 - 184页)。在此我们报告,用PDBu对A - 10细胞进行长时间处理(48小时)可显著增强AVP诱导的钙动员,但抑制ATP和凝血酶诱导的钙动员。PDBu(400 nM)使3 nM AVP诱导的[Ca²⁺]i增加了一倍,而AVP处理前后的基础钙浓度与未处理细胞的基础钙浓度并无差异。24小时暴露的半数有效浓度(EC50)为2.3 nM PDBu。佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯也有效,而4 - α - 佛波醇12,13 - 二十二酸酯(400 nM处理48小时)则无效。4 - α - 佛波醇12,13 - 二十二酸酯也不影响肌醇磷酸的形成。PDBu显著增强了AVP诱导的而非NaF诱导的肌醇磷酸形成。PDBu不影响基础肌醇磷酸和多磷酸肌醇水平,以及胞质和膜相关的磷脂酶C活性。PDBu处理(48小时,400 nM)使膜相关和胞质蛋白激酶C活性分别降低了80%和90%。然而,蛋白激酶C活性变化的剂量反应和时间进程与PDBu增强AVP诱导的钙动员的相同曲线并不相关。我们得出结论,长时间的PDBu处理选择性地增强了AVP诱导的钙动员和多磷酸肌醇水解。这些效应并非由加压素受体数量和表观亲和力的增加、磷脂酶C活性的增加、G蛋白 - 磷脂酶C偶联、多磷酸肌醇的形成或肌醇磷酸代谢酶的抑制所引起。AVP反应的增强与蛋白激酶C的脱敏或激活无关。我们认为,长时间的PDBu处理可能使一种假定的V1受体 - G蛋白 - 磷脂酶C复合物敏感化。